ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
37 hedge funds and large institutions have $98.3M invested in ESSA Pharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 13 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
17% more capital invested
Capital invested by funds: $84.1M → $98.3M (+$14.2M)
15% more call options, than puts
Call options by funds: $549K | Put options by funds: $477K
0.66% less ownership
Funds ownership: 75.72% → 75.06% (-0.66%)
18% less funds holding
Funds holding: 45 → 37 (-8)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.23M |
| 2 |
O
OrbiMed
New York
|
+$2.45M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$932K |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$810K |
| 5 |
Millennium Management
New York
|
+$719K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.68M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$1.69M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$1.52M |
| 4 |
D.E. Shaw & Co
New York
|
-$230K |
| 5 |
Two Sigma Investments
New York
|
-$123K |
EPIX Hedge Fund Activity: Q1 2023 in Review
37 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q1 2023, worth a combined $98.3M — up 17% from $84.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of EPIX and 5 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 11 added.
The largest buyer was Morgan Stanley, adding an estimated $3.23M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $4.68M sold.
- 37 institutional investors held ESSA Pharma (EPIX) as of Q1 2023, down from 45 in Q4 2022.
- Funds reported $98.3M of ESSA Pharma stock for Q1 2023, up 17% quarter-over-quarter.
- 5 funds opened new ESSA Pharma positions in Q1 2023 and 13 closed out, a net change of -8 holders.
- The largest ESSA Pharma buyer in Q1 2023 was Morgan Stanley, an estimated $3.23M added.
- The largest ESSA Pharma seller in Q1 2023 was Avidity Partners Management, an estimated $4.68M sold.
Based on aggregated 13F filings for Q1 2023.